Protection against oral challenge three months after i.v. immunization of BALB/c mice with live Aro Salmonella typhimurium and Salmonella enteritidis vaccines is serotype (species)-dependent and only partially determined by the main LPS O antigen.
The role of the main LPS O antigen in the specificity of protection as mediated by systemic mechanisms following immunization with live attenuated Aro Salmonella vaccines was studied in mice. Innately Salmonella-susceptible (Itys) BALB/c mice were immunized intravenously with a single dose of either Salmonella typhimurium SL3261 aroA (LPS O4,5,12) or Salmonella enteritidis Se795aroA (LPS O1,9,12), and challenged orally 2-3 months later with either S. typhimurium C5 or S. enteritidis Thirsk. Nearly isogenic transductants of the two challenge strains expressing either their own LPS or that of the other serotype (S. typhimurium C5 O4 or O9, and S. enteritidis Thirsk O9 or O4) were also used. Both vaccines conferred similar high protection against the virulent strain of the homologous serotype expressing its own LPS. There was no protection against the heterologous serotype expressing its own LPS. However, when vaccinated mice were challenged with either the same serotype as the vaccine but expressing the heterologous LPS, or with the heterologous serotype expressing the LPS of the vaccine, protection was always lower than protection against the fully homologous serotype. Anti-smooth LPS antibodies showed higher titres against the homologous LPS, but with significant crossreactivity with the heterologous LPS. Antibodies to O-rough S. typhimurium and S. enteritidis LPS were present following immunization with either of the two vaccine strains. The LPS alone cannot fully account for the specificity of protection in this model; other (protein) antigens may be responsible. It remains to be seen whether there is a T-cell mediated component to the specificity of protection conferred by live Salmonella vaccines.
Hormaeche
C E
CE
Department of Microbiology, Medical School, University of Newcastle, UK.
Mastroeni
P
P
Harrison
J A
JA
Demarco de Hormaeche
R
R
Svenson
S
S
Stocker
B A
BA
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial / Q000276:immunology*; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D007114:Immunization; D008070:Lipopolysaccharides / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D019081:O Antigens; D011105:Polyisoprenyl Phosphate Sugars / Q000276:immunology*; D012481:Salmonella Infections, Animal / Q000517:prevention & control*; D022562:Salmonella Vaccines; D012477:Salmonella enteritidis / Q000276:immunology* / Q000472:pathogenicity; D012486:Salmonella typhimurium / Q000276:immunology*; D013045:Species Specificity; D014436:Typhoid-Paratyphoid Vaccines; D014613:Vaccines, Attenuated / Q000627:therapeutic use; D014774:Virulence
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D008070:Lipopolysaccharides; D019081:O Antigens; C062656:O-specific polysaccharide, Salmonella; D011105:Polyisoprenyl Phosphate Sugars; D022562:Salmonella Vaccines; D014436:Typhoid-Paratyphoid Vaccines; D014613:Vaccines, Attenuated; C087350:aroA Salmonella vaccine